FRANKFORT, Ky. (Legal Newsline) - Kentucky Attorney General Jack Conway announced on Wednesday a $56.5 million settlement with Shire Pharmaceuticals after allegations that the company marketed off-label uses of Adderall XR, Vyvanse, Daytrona, Lialda and Pentasa.
Conway joined with other states and the federal government in the allegations. A civil suit was also filed alleging that Medicaid made erroneous payments because of the off-label marketing by Shire Medicaid.
Medicaid programs will receive $48.1 million from the settlement. Kentucky will receive $1.176 million.
"I will not tolerate pharmaceutical companies that try to mislead Kentuckians and our doctors while attempting to cheat our state Medicaid program," Conway said. "They will be held accountable. My job is to protect Kentucky taxpayers and our vital state programs from this type of misconduct and deceit."
Shire’s marketing and sales practices will be closely monitored by the U.S. Department of Health and Human Services and the Office of the Inspector under the Corporate Integrity Agreement (CIA) that was entered into under the terms of the settlement.
States, feds reach $56.5M settlement with company over Adderall marketing
